MindBio Therapeutics is a clinical stage drug development company that is pioneering psychedelic microdosing in multiple Phase 2B clinical trials. MB22001 is MindBio's lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing. Phase 2 clinical trials are underway. Clinical trials include: 1. Phase 2B trial in patients with Major Depressive Disorder 2. Phase 2B trial in patients with Late Stage Cancer and Depression The Phase 2B trial in patients with Major Depressive Disorder will evaluate the effectiveness of MB22001 in treating depression. We know from an open label Phase 2A trial in 20 patients with Major Depressive Disorder, that 53% of patients with depression were in complete remission from their depression at week 8. This is represented by a 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale). The 60% overall improvement in depressive symptoms and previous successful trials in healthy individuals gives the company confidence going into Phase 2B trials that MB22001 is a very promising treatment for Depression. The Phase 2 clinical trials for cancer patients will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.
External link for MindBio Therapeutics
91-97 William Street
Level 4
Melbourne , Victoria 3000, AU
MindBio Therapeutics reposted this
Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses. This week saw one of the globe’s top five biggest pharmaceutical companies – AbbVie – enter the market, while Enveric Biosciences, Inc. and MindBio Therapeutics signed a $66.5 million deal. Find out more. 👇
MindBio Therapeutics reposted this
This morning's news: Enveric Biosciences, Inc. Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders https://lnkd.in/eqFAFSnY
MindBio Therapeutics reposted this
Taking great companies public on global stock exchanges. And, I am on a mission to enhance global wellness and improve treatments for mental health conditions.
🔥 This is a terrific collaboration between NASDAQ listed Enveric Biosciences (NASDAQ: ENVB) and MindBio Therapeutics (CNSX: MBIO). https://lnkd.in/dptxy-Jv
MindBio Therapeutics reposted this
Co-Founder @ HLTH Communications | Amplifying Your Impact with Media Relations | Qwoted Top PR Practitioners
MindBio Therapeutics explores psychedelic potential of LSD for depression, PMS writes Tamra Sami for Clarivate's BioWorld The use of psychedelics is seeing impressive results in treating psychiatric disorders like treatment-resistant depression and post-traumatic stress disorder, and Mindbio Therapeutics is expanding the field to include microdoses of lysergic acid diethylamide (LSD) to treat depression and premenstrual syndrome. 📰 Read full article: https://lnkd.in/dV5PsAs9
MindBio Therapeutics reposted this
Taking great companies public on global stock exchanges. And, I am on a mission to enhance global wellness and improve treatments for mental health conditions.
The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women. Tune into Dr Rachael Sumner, who discusses the issues and the team's approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).
MindBio Therapeutics reposted this
Taking great companies public on global stock exchanges. And, I am on a mission to enhance global wellness and improve treatments for mental health conditions.
It's a marathon in clinical research, and despite market conditions the progress in the company's clinical work has been exceptionally strong. MindBio Therapeutics has a multiple Phase 2B clinical trial program underway and is making terrific progress with novel treatments for depressive disorders. 🔥 Now Canadian Securities Exchange listed MindBio Therapeutics (CNSX:MBIO) is exploring a senior exchange listing as it readies for Phase 3 trials. 🙏 Grateful for the support of investors, colleagues, friends and supporters as this Hardenbrook Group portfolio company enters its next stage of growth.
MindBio Therapeutics reposted this
Taking great companies public on global stock exchanges. And, I am on a mission to enhance global wellness and improve treatments for mental health conditions.
👩🏫 Women are under-represented in clinical research particularly early stage medical research, due to a number of reasons, pregnancy, menstrual cycle and other excuses. The approach in clinical science has surprised me, even in our own work, that men are more commonly used in early research and women are introduced in later trials. It's no surprise then that women are over represented compared to men in serious adverse events and side effects from prescribed medications. 🔥 So, in what appears to a first of its kind, certainly with this type of medicine, our team have designed and had approved a series of CNS medicine trials focused on women's health assessing the pharmacokinetic and pharmacodynamic effects of a CNS medicine over key phases of the menstrual cycle. 📣 The trials will study the effects of microdosing MB22001 in healthy menstruating persons and people suffering from Pre-Menstrual Syndrome and Pre-Menstrual Dysphoric Disorder. The symptoms of PMS and PMDD only exist as a result of and are exacerbated by certain stages by the menstrual cycle. 😀 The thesis is that during the luteal phase of the menstrual cycle (where the negative mood symptoms of PMS and PMDD symptoms escalate) microdosing of MB22001 will help alleviate the symptoms of PMS and PMDD without the side effects of commonly used antidepressants and the oral contraceptive pill. It's a significant development for progressing CNS medicine research in women's health.
MindBio Therapeutics reposted this
MindBio Therapeutics Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry: https://lnkd.in/dD2V-VrJ